House subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine.
The report on Emergent BioSolutions' Baltimore factory found an array of problems, from peeling paint to inadequate measures to prevent cross-contamination. Manufacturing at the facility is on hold.
Emergent BioSolutions is under contract with Operation Warp Speed to make COVID-19 vaccines, but the terms could allow employees and their families to get vaccinated ahead of schedule.
